November 01, 2018
Rose
GlaxoSmithKline reports that demand for Shingrix -- the drugmaker's new shingles vaccine that was granted favored status by the Centers for Disease Control and Prevention last year -- is driving healthy profits.
from Kaiser Health News https://ift.tt/2RvILWF
November 01, 2018
Rose
Health News, Kaiser Health News
No comments
Related Posts:
Big Investors Push Nursing Homes to Upgrade Care and Working Conditions- Time to Say Goodbye to Some Insurers’ Waivers for Covid Treatment Fees
- Evaluating President Joe Biden’s First 100 Days in Office
- ‘We’re Coming for You’: For Public Health Officials, a Year of Threats and Menace
- ‘Red Flag’ Gun Laws Get Another Look After Indiana, Colorado Shootings
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment